Nada Khaled M, Nishi Shawn
Department of Internal Medicine, Division of Pulmonary Critical Care & Sleep Medicine, The University of Texas Medical Branch, Galveston, TX.
Mayo Clin Proc Innov Qual Outcomes. 2020 Dec 11;5(1):177-186. doi: 10.1016/j.mayocpiqo.2020.09.009. eCollection 2021 Feb.
Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems and no clear benefit of one over the other. This article provides an overview of the two largest prospective trials performed with the FDA-approved valve systems.
内镜下肺减容术现已被纳入重度慢性阻塞性肺疾病的治疗指南。自2018年12月以来，已有两种瓣膜系统获得美国食品药品监督管理局（FDA）批准。迄今为止，尚无比较这两种瓣膜系统的头对头试验，也没有明确表明哪种系统更具优势。本文概述了使用FDA批准的瓣膜系统进行的两项最大规模的前瞻性试验。
